TABLE 1.
Patient characteristics
| AR (n = 60) | Non-AR (n = 161) | P | |
|---|---|---|---|
| Age at transplant (y) | 51.69 (30.42, 63.05) | 56.37 (46.00, 62.00) | 0.199 |
| Caucasian race (%) | 43 (71.7) | 132 (82.0) | 0.092 |
| Male sex (%) | 27 (45.0) | 101 (62.7) | 0.026 |
| Primary liver diagnosis (%) | |||
| Hepatitis C (nonviremic) | 5 (8.5) | 4 (3.1) | 0.248 |
| Alcohol | 8 (13.6) | 30 (23.4) | |
| Nonalcoholic fatty liver or cryptogenic | 10 (16.9) | 50 (39.1) | |
| Immune-mediated (PSC, AIH, PBC) | 10 (16.9) | 18 (14.1) | |
| Other | 26 (44.1) | 26 (20.3) | |
| Months from LT | 11.62 (5.44, 29.91) | 10.43 (5.70, 34.37) | 0.977 |
| Immunosuppression | |||
| CNI therapy | 47 (78.3) | 131 (81.4) | 0.752 |
| Mycophenolic acid therapy | 37 (61.7) | 91 (56.5) | 0.592 |
| Laboratory values | |||
| ALT (U/L) | 201.00 (136.00, 369.75) | 27.00 (18.00, 76.00) | <0.001 |
| Alkaline phosphatase (U/L) | 205.00 (142.25, 381.00) | 95.00 (67.00, 164.00) | <0.001 |
| Total bilirubin (mg/dL) | 1.20 (0.50, 4.40) | 0.70 (0.40, 1.10) | 0.001 |
| Creatinine (mg/dL) | 1.21 (0.57) | 1.26 (0.61) | 0.562 |
| Rejection characteristics | |||
| Mild (RAI 3–4) (%) | 26 (43%) | — | — |
| Moderate–severe (RAI 5–9) (%) | 34 (57%) | — | — |
AIH, autoimmune hepatitis; ALT, alanine aminotransferase; AR, acute rejection; CNI, calcineurin inhibitors; LT, liver transplant; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; RAI, rejection activity index.